Key result
Intracoronary administration of abciximab reduced the relative risk of major cardiovascular events by 45% (RR 0.55) compared to intravenous therapy in patients with acute coronary syndrome.
Why the study?
Does intracoronary administration of abciximab reduce major cardiovascular events in patients with acute coronary syndrome compared to intravenous administration?
Meta-Analysis (n=3,916)
Does intracoronary administration of abciximab reduce major cardiovascular events in patients with acute coronary syndrome compared to intravenous administration?
Intracoronary administration of abciximab significantly reduces the risk of major cardiovascular events, reinfarction, and congestive heart failure compared to intravenous administration in patients with acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Supports intracoronary abciximab in ACS; confirms MACE reduction versus intravenous administration across trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2013) conducted a meta-analysis in Acute Coronary Syndrome (n=3,916). Intracoronary abciximab vs. Intravenous abciximab was evaluated on Major cardiovascular events (RR 0.55, 95% CI 0.40-0.76, p=<0.001). Intracoronary administration of abciximab reduced the relative risk of major cardiovascular events by 45% (RR 0.55) compared to intravenous therapy in patients with acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: